Several RCTs have found the effect of SGLT2-i on decreasing HbA1C, FPG, and body weight by inducing favorable glucosuria (urinary loss of approximately 200–300 kcal/d), compared with placebo or other glucose-lowering drugs (25-30). The gene discussed is SLC5A2; the disease is Glycosuria.